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List of abbreviations 
AD: Alzheimer’s Disease 
aMCI: amnestic mild cognitive impairment 
CI: Confidence Interval  
CN: Cognitively Normal 
DLB: Dementia with Lewy Bodies 
DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders, 3rd 
Edition, Revised 
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition 
FTD: Frontotemporal Dementia 
GDS: Geriatric Depression Scale 
HR: Hazard Risk 
LLD: Late-life Depression 
N-ADL: Nishimura’s Activities of Daily Living 
naMCI: Non-amnestic Mild Cognitive Impairment 
SD: Standard Deviation 
VaD: Vascular Dementia 
WAIS-R: Wechsler Adult Intelligence Scale-Revised 
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Abstract 
Background: While longitudinal studies have investigated the relationships 
between mild cognitive impairment (MCI) subtypes and dementia subtypes, 
the results have been contradictory. In addition, some research shows that 
depression accompanied by MCI might increase the risk of Alzheimer’s 
disease (AD).  
Objective: The aim of this study is to longitudinally investigate the 
relationships between MCI subtypes and dementia subtypes, with special 
attention to the effect of comorbid depressive symptoms in a Japanese rural 
community. 
Methods: Non-demented participants (N=802) completed a baseline and 
follow-up study. Outcomes were conversion to dementia especially AD, MCI, or 
no conversion. A complementary log-log analysis was conducted to investigate 
the risk of dementia and AD in amnestic MCI (aMCI) compared to 
nonamnestic MCI (naMCI) groups. The impact of depressive symptoms on the 
transition from MCI to AD and from cognitively normal to MCI or AD was also 
analyzed.  
Results: The risk of developing dementia, in particular AD, for the aMCI 
group was significantly higher than that for the naMCI group. In the aMCI 
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group, the presence of depressive symptoms increased the risk of developing 
AD, but depressive symptoms in the naMCI group did not. In the cognitively 
normal group, the presence of depressive symptoms increased the risk of 
aMCI but not naMCI or AD. 
Conclusion: MCI subtyping could be useful in finding a prodrome for dementia 
and in particular for AD. The differing impacts of depressive symptoms on the 
development of AD suggest that the relationship between depressive 
symptoms and cognitive impairment could differ in aMCI and naMCI patients. 
 
Key words depressive symptoms, MCI, Alzheimer’s disease, conversion, 
community 
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Introduction 
Mild cognitive impairment (MCI) was conceptualized as a prodrome for 
Alzheimer’s disease (AD), so its original definition focused on memory 
impairment without other cognitive domain impairments [1]. However, based 
on the assumption that prodromal non-AD dementia might manifest cognitive 
impairments other than amnesia, the Key Symposium dichotomized MCI into 
subtypes: amnestic MCI (aMCI) single domain and multiple domain, and 
non-amnestic MCI (naMCI) single domain and multiple domain [2]. 
Accordingly, aMCI single domain is presumed to convert to AD, aMCI multiple 
domain to AD and vascular dementia (VaD), naMCI single domain to 
frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB), and 
naMCI multiple domain to DLB and VaD [2]. 
Longitudinal studies investigating the hypothesized relationship 
between MCI subtypes and dementia subtypes have reported contradictory 
results [3-9]. This might be due to selection bias, and verification of the 
hypothesized relationship should ideally be determined in a community-based 
longitudinal setting. However, only a few studies have satisfied this condition 
[5-9]. 
Several studies have examined what specific features of MCI might be 
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related to conversion to AD. For instance, some longitudinal studies reported 
that depression, which is often comorbid with MCI, was associated with 
increased risk of AD [10-13]. However, most of these focused on the transition 
from aMCI [10, 11, 13] and little attention has been paid to other subtypes of 
MCI.  
We hypothesized that aMCI has a strong relationship with AD, while 
naMCI does with non-AD dementia subtypes, and depressive symptoms may 
increase the risk of conversion to AD in both aMCI and naMCI. We initially 
investigated the hypothesized relationship between MCI subtypes and 
dementia subtypes in a Japanese community-based longitudinal setting. Next, 
we investigated the impact of depressive symptoms on the transition from 
aMCI and naMCI to AD or cognitively normal to aMCI, naMCI and AD. In 
order to ensure diagnostic accuracy, we employed brain magnetic resonance 
imaging (MRI) and brain single-photon emission computed tomography 
(SPECT). 
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Methods 
Subjects 
This study was based on the Tone Project [14-19]. Tone is a town located 
approximately 40 km northeast of Tokyo. Potential candidates were 3,083 
inhabitants aged 65 years and older as of 1 May 2001. The proportion of this 
age group in the total population (15.6%) was similar to the national average 
(17.2% in the 2000 Census).  
The inclusion criteria were that subjects were not demented at the end of 
the baseline study and that they at least participated in the first follow-up, 
and the second follow-up if not censored nor demented at the first one. The 
exclusion criteria were the presence of conditions that might affect cognitive 
function: psychiatric diseases (other than depression or depressive state), 
cerebrospinal meningitis, head injury, malignancy and substance abuse. 
Subjects were stratified by age, sex and education in years, and average scores 
and SD were calculated. 
Seven psychiatrists, eight psychologists and public health nurses were 
trained for the present study by the primary investigator. 
This study was approved by the University of Tsukuba ethics committee 
(No. 12/2001-11-26 and No.140/2007-11-6) and written informed consent was 
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obtained from all the participants. 
  
Clinical evaluation  
The baseline study conducted between December 2001 and April 2002 
is described elsewhere [14], so we have included a summary below. The first 
and the second follow-up studies were conducted between December 2004 and 
July 2005, and September 2008 and February 2009, respectively. The method 
of data collection was the same as that for the baseline study. 
 
Measures 
 
Demographic, medical and psychiatric assessment  
We administered a structured questionnaire and assessed 
demographics and the medical and psychiatric conditions of participants 
through self-report and inquiries with cohabitating family members. We also 
received information on the types of drugs taken by the participants at the 
time of assessments. Blood samples were taken for routine biochemical 
examination, complete blood count, and genotyping of apolipoprotein E 
(APOE). APOE ε4 was considered to be present when one or two APOE alleles 
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were ε4. 
 
Subjective cognitive complaints 
We used the Détérioration Cognitive Observée (DECO) scale to 
determine whether a participant had subjective cognitive complaints. DECO 
consists of 19 items, and was originally developed as an objective assessment 
of memory difficulty [20]. A participant having one or more positive items was 
considered to have subjective cognitive complaints. 
 
Activities of daily living (ADL) 
ADL was evaluated using Nishimura’s Activities of Daily Living 
(N-ADL) scale [21]. This scale determines the level of independence for five 
activities: gait/sitting, environment of activity, dressing/bathing, eating and 
excretion. Participants were considered to be functionally intact if they 
reported no difficulty with any of the five items. 
 
Neuropsychological battery  
All the participants underwent a group assessment using a battery of 
five tests, named 5-cog, measuring the following cognitive domains: attention, 
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memory, visuospatial function, language and reasoning. Attention was 
evaluated with the Japanese version of a set-dependent activity which 
assesses alternating attention, the capacity for mental flexibility that allows 
individuals to shift their focus of attention between tasks with different 
cognitive requirements [22]. In this test, there were three rows on the page 
(top, middle and bottom) with three Chinese characters that meant ‘‘top”, 
‘‘middle” or ‘‘bottom”. Some of the characters did not match their positions. 
The participants were required to circle the characters that were placed in 
the correct rows. Memory was assessed with the category cued recall test [23]. 
Participants were initially instructed to memorize 32 words with their 
categories. They were asked later to recall and write down words when 
provided a clue of the category. To evaluate visuospatial function, the clock 
drawing test was used [24]. It requires participants to draw a clock dial and 
hands showing the time at ten past eleven. We examined language ability 
with the category fluency test [25]. The participants were required to generate 
as many words as possible from animal category in two minutes. The total 
number of animals named was the score for the test. Reasoning ability was 
measured with the similarity subset of the Wechsler Adult Intelligence 
Scale-Revised (WAIS-R) [26]. The participants were given two words that 
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belong to a same category. Then they were asked to provide another word. 
 
Evaluation of depressive symptoms 
Depressive mood at baseline was measured using the 15-item short 
version of the Geriatric Depression Scale (GDS) [27, 28]. According to the 
results of this self-assessment, the participants were dichotomized into the 
depressed group and the non-depressed group; participants who scored 5 or 
more on the GDS were classified as depressed and those who scored less than 
5 as non-depressed [29]. Self-reported past history of depression and present 
psychotropic drugs use were also investigated thoroughly in the interview.  
 
MCI diagnosis 
Diagnoses of MCI were made for non-demented subjects at a consensus 
meeting involving healthcare professionals expert in dementia. The standard 
criteria for MCI were: a) cognitive complaints (defined previously), b) objective 
impairment in one or more cognitive domains (attention, memory, visuospatial 
function, language and reasoning) based on the average of the 5-cog scores 
within that domain and a cut-off of -1SD given the corrections for age, sex and 
years of education, c) essentially preserved ADL (defined previously), and d) 
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no diagnosis of dementia at the consensus meeting. Subtypes of MCI were 
determined according to the 5-cog subscale. aMCI was defined as a state 
where the memory subscale score was lower than 1 point below -1SD 
irrespective of the scores of other cognitive domains (attention, visuospatial 
function, language, and reasoning). naMCI was defined as a state where one 
or more non-memory subscale scores were lower than 1 point below -1SD, 
while the memory subscale score was normal. 
 
The diagnostic criteria for dementia 
After the follow-up cognitive examination, dementia was diagnosed 
according to the DSM-III-R criteria [30]. Once dementia was diagnosed, we 
determined the dementia subtypes (AD, DLB, VaD and FTD) based on the 
standard clinical criteria: the National Institute of Neurological and 
Communication Disorders and Stroke-Alzheimer’s Disease and Related 
Disorders Association Criteria (NINCDS-ADRDA criteria) for AD [31], the 
Consortium on Dementia with Lewy Bodies (CDLB) Guidelines for DLB [32], 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) for VaD 
[33], and the clinical consensus criteria for FTD [34]. 
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Consensus meeting to diagnose dementia  
A consensus meeting was held to confirm the diagnosis of dementia 
using clinical and neuroimaging data. Three psychiatrists, who are experts in 
dementia, discussed each case and made clinical diagnoses according to the 
diagnostic criteria. 
 
Statistical analysis 
In comparing the baseline characteristics, the continuous variables were 
not normally distributed. Thus, we employed the Mann-Whitney U test. The 
chi-square test or, if appropriate, Fisher’s exact test was used for categorical 
variables. To examine the risk of conversion to dementia, AD or MCI, we used 
a complementary log-log model [19]. While conversion to MCI, dementia or AD 
might occur at any time during the observation period, we could only identify 
such an outcome at one of the two fixed follow-up points. Thus, discrete time 
survival analysis as a complementary log-log model fits more appropriately 
than does continuous time survival analysis as a Cox proportional model. In 
addition, randomization is not required in the study design [35]. We first 
assessed the risk of dementia or AD for aMCI compared to naMCI (Analysis 1). 
Secondly, we investigated the impact of depressive symptoms using GDS 
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scores as depressed group (GDS≧5) vs non-depressed group (GDS<5) or as 
continuous variables on conversion to AD from MCI (Analysis 2), and that to 
MCI or AD from cognitive normality (Analysis 3). Analyses 1-1 was adjusted 
for age, sex, years of education and depressive state (defined as GDS≧5); 
Analysis 1-2 was adjusted for APOE ε4 and vascular risk factors including 
history of hypertension, diabetes mellitus, dyslipidemia and cerebrovascular 
disease. Analyses 2-1 and 3-1 were adjusted for age, sex, years of education; 
Analyses 2-2 and 3-2 were adjusted for APOE ε4 and vascular risk factors 
including history of hypertension, diabetes mellitus, dyslipidemia and 
cerebrovascular disease. 
 Data were analyzed using R software (Version 3.1.2). A statistical 
significance level of 0.05 was used for all the analyses. 
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Results 
General findings 
Of the 2,698 possible candidates, 1,844 (68.3%) met the criteria for 
participation at the completion of the baseline study. Three participants had a 
past history of depression according to their self-report. There were three 
current antidepressant users, but all of them were asymptomatic for 
depression at that time. We did not find any participants with anxiety 
disorder from their self-report and information from their family members. 
Among those depressive participants (GDS ≧ 5), one took anxiolytics. 
Unexpectedly, among those non-depressive participants (GDS ≺ 5), 3 took 
anxiolytics.  
Of these 1,844 baseline participants, 1,042 were excluded due to 
confirmed dementia at baseline (n=79), illnesses that might affect the 
cognitive functions described above (n=7), impaired ADL (n=132), lack of 
subjective cognitive complaints (n=57), incomplete data (n=129), and no 
follow-up (deceased: n=141, moved: n=33, declined: n=464). As a result, 802 
participants who underwent the first follow-up were included in the analysis 
(Figure 1). Compared to those included, those excluded were older (average 
75.5 vs 72.8 years), more often female (63.1% vs 56.2%), less educated (9.4 vs 
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10.2 years of school completed), and had higher GDS scores (3.4 vs 2.5) and 
higher rates of depressive state (GDS score≥5) (28.1% vs 18.1%) significantly 
(p<0.05 for all). 
Based on the baseline data, the participants were classified into 
cognitively normal (n=526), aMCI (n=90) and naMCI (n=186) groups. The 
rates of depressive state (GDS score≥5) for the cognitively normal, aMCI and 
naMCI groups were 15.4%, 24.4% and 22.6%, respectively. Comparisons of 
aMCI and naMCI groups showed that the former (72.0±4.9 years) was 
significantly younger than the latter (73.7±5.3 years) (p=0.01) (Table1). 
During 5.2±1.9 years of the follow-up period, 101 participants converted to 
dementia.  
 
Rates of Conversion to Dementia 
 Figure 2 shows the outcome of subjects who participated in both the 
baseline and the first follow-up studies. Of the total 101 participants who 
converted to dementia, 38 had been cognitively normal, 30 had been aMCI, 
and 33 had been naMCI at baseline. The rate of conversion to dementia from 
the cognitively normal group was 7.2%, from the aMCI group was 33.3%, and 
from the naMCI group was 17.7%. It is of note that some participants reverted 
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to normal cognition from MCI within the observation period: from the aMCI 
group, 26 (28.9%) reverted, and 80 (43.0%) reverted from the naMCI group. 
The reversion rate was higher for naMCI than aMCI (p=0.025). For all 
subjects, follow-up consensus meetings were held. As a result, a diagnosis 
consensus was reached. The converters were AD (n=68), VaD (n=16), DLB 
(n=14) and FTD (n=3) (Figure 2). 
 
Conversion to dementia or AD from aMCI and naMCI 
The numbers of converters to dementia were 38 out of 526 cognitively 
normal participants, 30 out of 90 participants with aMCI and 33 out of 186 
participants with naMCI. Those to AD alone were 29, 17 and 22, respectively. 
AD was the most frequent subtype of dementia for each baseline group. The 
conversion to non-AD dementia was not confined to naMCI (Figure 2); however, 
as shown in Table 2, compared to the naMCI group, the risk of converting to 
dementia for the aMCI group was more than double (HR=2.56, CI=1.46-4.49, 
p=0.0011). Risk of conversion to AD was about double (HR=2.27, CI=1.11-4.65, 
p=0.0254). 
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Conversion to AD from MCI in relation to depressive symptoms 
Compared to the non-depressed MCI group, the depressed MCI group 
had no significant risk of AD in the adjusted model. Compared to the 
non-depressed aMCI group, the depressed aMCI group had a significantly 
higher risk of AD (HR=11.37, CI=1.98-65.20, p=0.006). However, the presence 
of depressive symptoms did not affect the risk of AD among the naMCI group 
(Table 3). The results did not substantially change when using GDS as a 
continuous variable. 
 
Conversion to MCI or AD from cognitively normal in relation to depressive 
symptoms 
 The presence of depressive symptoms did not increase the risk of 
converting to MCI or naMCI for cognitively normal participants (Table 4). 
However, the presence of depressive symptoms did increase the risk of 
converting to aMCI by nearly 5 times (HR=4.86, CI=1.55-15.69, p=0.007). 
There was no significant difference in the risk of converting to AD between 
non-depressed and depressed cognitively normal groups (HR=1.18, 
CI=0.50-2.83, p=0.705). The results did not substantially change when using 
GDS as a continuous variable. 
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Discussion  
 Here we considered depressive symptoms while examining the 
hypothesized relationship between MCI subtypes and dementia subtypes. In 
our study, there was a higher risk of converting to dementia and AD in the 
aMCI group than in the naMCI group. We also found that depressive 
symptoms increased the risk of conversion to AD only in the aMCI group. 
Depressive symptoms also increased the risk of conversion to aMCI, but not to 
naMCI or AD among participants who were cognitively normal at baseline. 
The relationships between MCI subtypes and dementia subtypes are 
contradictory. A clinic-based study reported that MCI subtype had a major 
influence on the subsequent type of diagnosed dementia [4], whereas a 
majority of community-based studies only partially support this hypothesis 
[5-8]. A community study in Austria, investigating the prognostic validity of 
aMCI and naMCI in the prediction of AD, VaD and mixed dementia, reported 
that the hypothesis could be confirmed only for aMCI and incident AD [8]. Our 
present study strengthens this finding.  
The current results also showed that the presence of depressive 
symptoms increased the risk of aMCI converting to AD. While similar findings 
have been reported [10, 11, 13], our results additionally showed that this was 
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not the case with naMCI.  There is a possible explanation for this. Steffens 
reviewed the relationship between brain regions and depression syndromes, 
and paid particular attention to the following regions: orbitofrontal cortex, 
anterior cingulate gyrus, dorsolateral prefrontal cortex and hippocampus [36]. 
Among these four regions, the hippocampus is strongly associated with 
memory function. Neuroimaging studies have shown hippocampal volume of 
elderly individuals with aMCI is smaller than that of cognitively normal 
elderly, but that of elderly individuals with naMCI not so [37, 38]. An MRI 
study on major depressive disorders reported that reduced hippocampal 
volumes were associated with deficits in visual and verbal memory 
performance [39]. A recent study investigating participants with lifetime 
major depression and remitted or mild symptoms reported that MCI was 
found in 75.7% and memory change was linked to hippocampal atrophy in the 
patients [40]. The main lesions of incipient AD are located in the hippocampus 
and its neighboring regions. Taking these findings together, in considering 
aMCI alone, aMCI comorbid with depressive symptoms may indicate a higher 
probability of hippocampal involvement as a background lesion. Jorm and 
colleagues, along with Butters and colleagues hypothesized several 
mechanisms that might link depression and dementia: (1) depression may be a 
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prodrome of dementia, (2) depression can unmask clinical manifestation of 
dementing diseases, and (3) depression can cause hippocampal damage 
through raised cortisol levels [41, 42]. These hypotheses are not mutually 
exclusive, and involvement of the hippocampus may underlie in the case of 
incipient AD.  
On the other hand, why depressive symptoms did not increase the risk of 
conversion to AD in the naMCI group also deserves attention. One possible 
explanation is that naMCI per se could be an unstable state, which tends to 
revert to normal cognition [5]. In the current study, 43.0% of the subjects with 
naMCI at baseline reverted to normal cognition within the observation period, 
a figure which is significantly higher than for aMCI (28.9%). On the other 
hand, according to a study of late-life depression (LLD), 94% of the subjects 
with a current episode of unipolar major depression and cognitive 
impairments at baseline still remained cognitively impaired at one year 
despite their remission [43], suggesting heterogeneity in cognitive course and 
outcomes in LLD [44]. Following patients with DSM-IV major depressive 
disorder for at least 18 months, half of them were found to have generalized 
cognitive impairment compared to healthy controls including memory, 
processing speed and executive function [45]. The authors showed that 
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impaired processing speed might be a partial mediator of deficits in other 
cognitive domains, but did not fully explain the difference between patients 
and controls; other deficits could exist in parallel. A study investigating 
relationships between cognitive function of major depressive disorder and 
subsequent diagnosis of AD longitudinally reported that recall of verbal 
contextual information was associated with AD to a greater extent than 
executive functioning [46]. The frontally mediated mild cognitive impairment 
may not predict conversion to Alzheimer’s disease in geriatric depression [47]. 
Taken those findings and ours together, the regions responsible for concurrent 
nonamnestic impairment in depressive state might be areas other than 
hippocampus.  
It is possible that aMCI with depressive symptoms might be a reliable 
prodrome of AD, while naMCI with depressive symptoms may not. Our results 
showed that the relationship between aMCI and subsequent AD could be 
better elucidated with the presence of depressive symptoms.  
Similar to our study, Richard and colleagues’ community-based study 
investigated depression and subsequent dementia in MCI subtypes, but with 
different results [48]. They showed that patients with MCI comorbid with 
depression at baseline had a higher risk of progression to VaD, but not to AD. 
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Their study focused on cerebrovascular disease as a potential link between 
depression and dementia. Sampling may explain the inconsistency between 
their results and ours, since there was a higher burden of hypertension (48% 
vs 28%) and diabetes mellitus (19% vs 6%). Participants in their community 
study were also older (77 vs 73 years old), and ethnically different (White, 
Black and Hispanic vs Mongoloid only). A meta-analysis of community-based 
cohort studies conducted by Diniz et. al reported that individuals with 
depression were at much higher risk for converting to VaD compared to AD 
[49]. Different from these studies, we especially focused on MCI samples. 
Relatively lower incidence of VaD in the present study also might have 
prevented from duplicating the finding. 
Next, in our study, the presence of depressive symptoms in the 
cognitively normal group increased the risk of conversion to aMCI, but not to 
naMCI or collective MCI. While some previous studies have reported that 
depression increased the risk of conversion to MCI in cognitively normal 
participants [50, 51], another did not [48]. A recent large population-based 
study found that depression at baseline increased the risk of incident aMCI 
but not naMCI, a finding consistent with our result [52]. Considering aMCI 
itself has a high risk of AD, depressive symptoms antecedent to aMCI may be 
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a sign of prodromal AD. Alternatively, depressive symptoms and associated 
neuropathology (e.g. reduced hippocampal volume) might reduce cognitive 
reserve, and thereby unmask the manifestation of underlying AD. 
In terms of limitations, we have no autopsy cases and the 
neuropathological background of dementia cases remains unknown. Secondly, 
participants excluded from the analysis were older, more often female, less 
educated, and had higher GDS scores and higher rates of depressive state 
(GDS score≥5) than included participants. While these characteristics may 
precipitate the conversion to dementia, we adjusted all of these covariates in 
the analysis. The past history of depression was based on participants’ 
self-report. Assessment of depressive illness according to DSM criteria or a 
similar rigorous gold standard instrument was not included in the current 
study. Our definition of depressive cases at baseline were based on GDS scores. 
A cut-off score of GDS≧5 could be a mild depressive state and that might 
affect the results. Moreover, the ADL measure we used (N-ADL) targeted basic 
ADLs and was different from more complex instrumental ADLs (IADLs), 
which could have led to misidentification of some individuals as normal rather 
than MCI or dementia. We did not take into account psychosocial factors such 
as participants’ personality, life style, environment, life events and so on. For 
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adjustment of 5-cog, we excluded dementia cases from participants of the Tone 
project for reference (non-dementia cases). Not only cognitively normal cases, 
but also MCI cases were included in the reference. This would result in some 
degree of circulatory. Lastly, the number of events was relatively small in our 
study. Future reconfirmation with participants with major depression, IADL 
information, psychosocial information, truly independent normative data from 
the sample in the analysis or in a larger sample is desirable to generalize 
these results.  
In conclusion, MCI subtyping could be useful only in finding a prodrome 
for AD. The differing impacts of depressive symptoms on the development of 
AD appear to suggest that the relationship between depressive symptoms and 
cognitive impairment for aMCI and naMCI could differ. The relationship 
between aMCI and subsequent AD could be more clearly elucidated with the 
presence of depressive symptoms. 
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Table 1 
Baseline characteristics of all participants (n=802) 
   CN  aMCI  naMCI 
Characteristics  n=526  n=90  n=186  p-value1 
Age, y, mean±SD 72.7±5.1  72.0±4.9  73.7±5.3  0.01 
Female, n (%)  287 (54.6) 55 (61.1) 109 (58.6) 0.69 
Education, y, mean±SD 10.3±2.6  9.5±2.4  10.0±2.8  0.26 
GDS≥5, n (%)  81 (15.4) 22 (24.4) 42 (22.6) 0.73 
GDS score, mean±SD 2.2±2.3  2.9±2.3  3.0±2.4  0.72 
BMI, kg/㎡, mean±SD 23.1±3.1  23.2±3.0  22.8±3.1  0.33 
CVD, n (%)  19 (3.6)  4 (4.4)  5 (2.7)  0.48 
Hypertension, n (%) 152 (28.9) 21 (23.3) 50 (26.9) 0.53 
Diabetes Mellitus, n (%) 23 (4.4)  4 (4.4)  20 (10.8) 0.08 
Dyslipidemia, n (%) 22 (4.2)  1 (1.1)  5 (2.7)  0.67 
Smoking, n (%)  198 (37.6) 33 (36.7) 61 (32.8) 0.53 
Alcohol, n (%)  194 (36.9) 36 (40.0) 64 (34.4) 0.37 
APOEε4 carrier, n (%)2 86 (17.2) 17 (21.8) 36 (20.7) 0.84 
1Chisquare or Fisher’s exact test and the Mann-Whitney U test for comparisons 
between aMCI and naMCI. 2n=501 for cognitively normal, n=78 for aMCI and n=174 for 
naMCI. CN, cognitively normal; MCI, mild cognitive impairment; aMCI, amnestic MCI; 
naMCI, nonamnestic MCI; GDS, Geriatric Depression Scale; BMI, body mass index; 
CVD, cerebrovascular disease; APOE, apolipoprotein E. 
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Table 2 
Risk of dementia in participants with amnestic MCI compared to nonamnestic MCI at baseline 
                
    Analysis1-11     Analysis 1-22 
    At risk Cases HR (95% CI) p-value  At risk Cases HR (95% CI) p-value 
Conversion to all dementia 276 63     252 58 
naMCI   186 33 1 (Reference)   174 32 1 (Reference) 
aMCI    90 30 2.74 (1.62-4.62) 0.0002   78 26 2.56 (1.46-4.49) 0.0011 
Conversion to AD only  276 39     252 36 
 naMCI   186 22 1 (Reference)   174 21 1 (Reference) 
  aMCI    90 17 2.05 (1.06-3.98) 0.0337   78 15 2.27 (1.11-4.65) 0.0254 
1Adjusted for age, sex, years of education and depressive state (defined as GDS≧5). 2Adjusted for age, sex, years of education, 
depressive state (defined as GDS≧5), apolipoprotein E (APOE) ε4 and vascular risk factors including history of hypertension, diabetes 
mellitus, dyslipidemia and cerebrovascular disease. The difference in numbers of participants at risk between Analysis 1-1 and Analysis 
1-2 was due to missing data on the APOE genotype. HR, hazard ratio; CI, confidence interval; MCI, mild cognitive impairment; aMCI, 
amnestic MCI; naMCI, nonamnestic MCI. 
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Table 3 
Risk of Alzheimer’s disease in relation to depressive symptoms among participants with MCI at baseline 
   Analysis 2-11     Analysis 2-22 
   At risk Cases HR (95% CI)  p-value At risk Cases HR (95% CI)  p-value 
MCI   252 39     230 36 
GDS＜5  198 25 1 (Reference)   179 23 1 (Reference) 
   GDS≧5   54 14 2.15 (1.10-4.20) 0.025   51 13 1.74 (0.82-3.70)  0.148 
GDS score3 252 39 1.12 (0.99-1.27) 0.066  230 36 1.10 (0.96-1.27)  0.179 
  
aMCI    77 17      67 15 
 GDS＜5   60  9 1 (Reference)    51  8 1 (Reference) 
   GDS≧5   17  8 7.79 (2.35-25.84) 0.0008   16  7 11.37 (1.98-65.20) 0.006 
GDS score3  77 17 1.27 (1.04-1.55) 0.0187   67 15 1.30 (1.00-1.70)  0.054 
 
naMCI   175 22     163 21 
 GDS＜5  138 16 1 (Reference)   128 15 1 (Reference) 
   GDS≧5   37   6 1.35 (0.52-3.48) 0.535   35  6 0.99 (0.37-2.71)  0.992 
GDS score3 175 22 1.08 (0.91-1.27) 0.370  163 21 1.02 (0.84-1.24)  0.853 
1Adjusted for age, sex, years of education. 2Adjusted for age, sex, years of education, apolipoprotein E (APOE) ε4 and vascular risk 
factors including history of hypertension, diabetes mellitus, dyslipidemia and cerebrovascular disease. 3Geriatric Depression Scale 
(GDS) score examined as a continuous variable in 1-point increment. The difference in numbers of participants at risk between Analysis 
2-1 and Analysis 2-2 was due to missing data on the APOE genotype. HR, hazard ratio; CI, confidence interval; MCI, mild cognitive 
impairment; aMCI, amnestic MCI; naMCI, nonamnestic MCI; GDS, Geriatric Depression Scale. 
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Table 4 
Risk of mild cognitive impairment in relation to depressive symptoms among cognitively normal participants at 
baseline 
                
   Analysis 3-11     Analysis 3-22 
   At risk Cases HR (95% CI) p-value  At risk Cases HR (95% CI) p-value 
Conversion to all MCI 488 76     465 73 
 GDS<5  417 64 1 (Reference)   396 61 1 (Reference) 
 GDS≧5   71 12 1.10 (0.58-2.06) 0.770   69 12 1.20 (0.63-2.27) 0.581 
 GDS score3 488 76 1.09 (0.99-1.19) 0.089  465 73 1.11 (1.01-1.23) 0.031 
Conversion to aMCI 427 15     407 15 
 GDS<5  363 10 1 (Reference)   345 10 1 (Reference) 
 GDS≧5   64  5 3.50 (1.13-10.82) 0.029   62  5 4.86 (1.55-15.19) 0.007 
 GDS score3 427 15 1.24 (1.01-1.52) 0.039  407 15 1.33 (1.07-1.65) 0.009 
Conversion to naMCI 473 61     450 58 
 GDS<5  407 54 1 (Reference)   386 51 1 (Reference) 
 GDS≧5   66  7 0.74 (0.33-1.65) 0.461   64  7 0.81 (0.36-1.83) 0.609 
 GDS score3 473 61 1.05 (0.95-1.17) 0.338  450 58 1.08 (0.97-1.21) 0.154 
1Adjusted for age, sex, years of education. 2Adjusted for age, sex, years of education, apolipoprotein E (APOE) ε4 and vascular risk 
factors including history of hypertension, diabetes mellitus, dyslipidemia and cerebrovascular disease. 3Geriatric Depression Scale 
(GDS) score examined as a continuous variable in 1-point increment. The difference in numbers of participants at risk between Analysis 
3-1 and Analysis 3-2 was due to missing data on the APOE genotype. HR, hazard ratio; CI, confidence interval; MCI, mild cognitive 
impairment; aMCI, amnestic MCI; naMCI, nonamnestic MCI; GDS, Geriatric Depression Scale. 
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    Figure 1. Flow diagram of the sample selection 
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   Figure 2. Outcome of the cohort within the observation period 
